Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? A Large Cohort from a Latin America Referral Center

Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included. We assume patients who relapse in the first 5 years of follow-up could have a positive genetic test. As risk factors for relapse, ergo positive genetic test, we consider those patients who presented multifocal, bilateral, or previous renal tumor. Of 2,232 nephrectomies for kidney cancer, 301 patients met the inclusion criteria. The median follow-up was 60 months (IQR 29-101). The estimated five-year RFS was 94.4% (95% CI 91.3-97.5). Tumor size, previous renal tumor, multifocality, bilaterality, and pT3 or pT4 stage were independent recurrence risk factors. Genetic testing was performed on 24 patients. 10 patients had pathogenic variants in the test, 8 of which recurred during their life. 46-year-old cut-off has shown low performance in genetic testing. Therefore, we recommend that it be considered only if other hRCC risk criteria exist. Multifocality, bilaterality, and previous renal tumor could predict a positive genetic test.

[1]  Mark W. Ball,et al.  Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement , 2021, Cancer.

[2]  U. Capitanio,et al.  Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium , 2021, World Journal of Urology.

[3]  S. Hancock,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  M. Ferguson,et al.  Clinical predictors of a positive test result in patients undergoing genetic evaluation for a hereditary kidney cancer syndrome. , 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[5]  B. Shuch,et al.  Genetic Testing in Kidney Cancer Patients: Who, When, and How? , 2019, European urology focus.

[6]  E. Maher Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management , 2018, World Journal of Urology.

[7]  B. Shuch,et al.  Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test , 2017, Cancer.

[8]  P. Humphrey,et al.  Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features , 2015, The American journal of surgical pathology.

[9]  G. Bratslavsky,et al.  Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations , 2014, World Journal of Urology.

[10]  W. Linehan,et al.  Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Pautler,et al.  Canadian guideline on genetic screening for hereditary renal cell cancers. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[12]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[13]  S. Kessler,et al.  Attitudes of persons at risk for Huntington disease toward predictive testing. , 1987, American journal of medical genetics.

[14]  V. Wong,et al.  Von Hippel-Lindau Disease: Clinical and Pathological Manifestations in Nine Families With 50 Affected Members , 1976 .

[15]  S. Pautler,et al.  Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[17]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .